Biotech Values

[DonShimoda]

The duration data released today really go a long way toward clarifying Ponatinib's commercial opportunity. Making a case for Ponatinib over sprycel or tasigna in 2nd line just got a whole lot easier. The 92% MCyr in patients with T315I mutation is jaw dropping and says a lot about the company's drug discovery capability. My guess is that many analysts are waiting for the anticipated first read on the PACE trial expected at ASH but, imo, today's data was possibly more important.